PDS Biotechnology Corp PDSB

US Biotechnology
$0.80 β–Ό -0.38% ($0.00)
Open $0.80
Prev Close $0.80
Day Range $0.78 – $0.82
52W Range $0.20 – $1.55
Market Cap $44.61M
Beta 1.43
EPS (TTM) $-0.65

πŸ“‹ Company Profile

IndustryBiotechnology
CountryUS
ExchangeNASDAQ NMS - GLOBAL MARKET
CurrencyUSD
IPO Date2015-10-01
Shares Out.55,920,000
Websitepdsbiotech.com β†—
Phone13026587581
Employees21
Revenue$0
Gross Profit$0
Net Income-$9.8M
Free Cash Flow-$16.8M
Total Assets$8.8M
Total Liabilities$12.4M
Equity-$3.6M
About PDS Biotechnology Corp

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.

PDS Biotechnology Corp is a publicly traded company under the ticker symbol PDSB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.

πŸ“Š Analyst Ratings

9 analysts (2026-09-01)

Strong Buy 2
Buy 6
Hold 1

πŸ“° Latest News for PDSB

πŸ‘₯ Related Stocks